Crescent Biopharma (CBIO) Receivables - Other (2016 - 2025)
Crescent Biopharma (CBIO) has disclosed Receivables - Other for 11 consecutive years, with $78762.0 as the latest value for Q1 2025.
- Quarterly Receivables - Other fell 28.36% to $78762.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $78762.0 through Mar 2025, down 28.36% year-over-year, with the annual reading at $175820.0 for FY2023, 22.08% up from the prior year.
- Receivables - Other for Q1 2025 was $78762.0 at Crescent Biopharma, up from $50255.0 in the prior quarter.
- The five-year high for Receivables - Other was $444568.0 in Q1 2021, with the low at $1347.0 in Q4 2021.
- Average Receivables - Other over 5 years is $121182.9, with a median of $100138.5 recorded in 2022.
- Peak annual rise in Receivables - Other hit 10591.61% in 2022, while the deepest fall reached 98.93% in 2022.
- Over 5 years, Receivables - Other stood at $1347.0 in 2021, then soared by 10591.61% to $144016.0 in 2022, then grew by 22.08% to $175820.0 in 2023, then crashed by 71.42% to $50255.0 in 2024, then surged by 56.72% to $78762.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $78762.0, $50255.0, and $76710.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.